FKA-9i is an orally active anticancer agent. FKA-9i directly binds to and promotes the degradation of oncoproteins LRPPRC (kd: 7.387 µM), YBX1 (kd: 16.52 µM) and RPN1 (kd: 26.82 µM). FKA-9i inhibits the MAPK signaling pathway and mitochondrial oxidative phosphorylation. FKA-9i also induces cancer cell cycle arrest, apoptosis, mitochondrial dysfunction and ROS accumulation. FKA-9i can be used in the research of tumors such as gastric cancer[1].
Molekulargewicht:
660.66
CAS Nummer:
[3060515-85-4]
Formel:
C30H26F2N2O9S2
Target-Kategorie:
Apoptosis,Bcl-2 Family,Caspase,CDK,p38 MAPK,Reactive Oxygen Species (ROS)
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
